Credit Suisse’s BioCryst Pharmaceuticals BCRX Stock Holding History

Credit Suisse’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$1.17M	Hold	229,544	–	–	﹤0.01%	2172
2023 Q4	$1.37M	Sell	229,544 -1,507	-0.7%	-$8.73K	﹤0.01%	2130
2023 Q3	$1.64M	Sell	231,051 -50,966	-18%	-$366K	﹤0.01%	1957
2023 Q2	$1.99M	Buy	282,017 +20,984	+8%	+$168K	﹤0.01%	1915
2023 Q1	$2.18M	Buy	261,033 +8,782	+3%	+$84.5K	﹤0.01%	1812
2022 Q4	$2.9M	Buy	252,251 +2,743	+1%	+$34.2K	﹤0.01%	1662
2022 Q3	$3.14M	Buy	249,508 +2,570	+1%	+$33.1K	﹤0.01%	1548
2022 Q2	$2.61M	Sell	246,938 -10,851	-4%	-$112K	﹤0.01%	1726
2022 Q1	$4.19M	Buy	257,789 +13,881	+6%	+$223K	﹤0.01%	1589
2021 Q4	$3.38M	Sell	243,908 -503,137	-67%	-$6.66M	﹤0.01%	2346
2021 Q3	$10.7M	Buy	747,045 +31,016	+4%	+$489K	0.01%	1490
2021 Q2	$11.3M	Buy	716,029 +479,982	+203%	+$6.52M	0.01%	1479
2021 Q1	$2.4M	Sell	236,047 -169,719	-42%	-$1.75M	﹤0.01%	2680
2020 Q4	$3.02M	Sell	405,766 -876,380	-68%	-$4.52M	﹤0.01%	2516
2020 Q3	$4.4M	Buy	1,282,146 +515,059	+67%	+$2.21M	﹤0.01%	1875
2020 Q2	$3.65M	Sell	767,087 -107,304	-12%	-$429K	﹤0.01%	1916
2020 Q1	$1.75M	Sell	874,391 -727,924	-45%	-$2M	﹤0.01%	2223
2019 Q4	$5.53M	Buy	1,602,315 +430,876	+37%	+$1.08M	﹤0.01%	1812
2019 Q3	$3.36M	Buy	1,171,439 +1,023,363	+691%	+$3.18M	﹤0.01%	2070
2019 Q2	$560K	Sell	148,076 -22,881	-13%	-$138K	﹤0.01%	3334
2019 Q1	$1.39M	Buy	170,957 +71,362	+72%	+$611K	﹤0.01%	2644
2018 Q4	$804K	Buy	99,595 +60,800	+157%	+$473K	﹤0.01%	2955
2018 Q3	$296K	Sell	38,795 -23,622	-38%	-$159K	﹤0.01%	3528
2018 Q2	$358K	Sell	62,417 -23,597	-27%	-$130K	﹤0.01%	3567
2018 Q1	$411K	Buy	86,014 +16,444	+24%	+$84.5K	﹤0.01%	3454
2017 Q4	$342K	Sell	69,570 -26,677	-28%	-$129K	﹤0.01%	3581
2017 Q3	$505K	Sell	96,247 -10,071	-9%	-$51.6K	﹤0.01%	3516
2017 Q2	$590K	Sell	106,318 -4,519	-4%	-$27.5K	﹤0.01%	3035
2017 Q1	$931K	Buy	110,837 +46,204	+71%	+$321K	﹤0.01%	2917
2016 Q4	$409K	Sell	64,633 -46,772	-42%	-$243K	﹤0.01%	3536
2016 Q3	$492K	Sell	111,405 -18,166	-14%	-$72.6K	﹤0.01%	3432
2016 Q2	$367K	Buy	129,571 +44,652	+53%	+$139K	﹤0.01%	3591
2016 Q1	$242K	Buy	84,919 +27,509	+48%	+$122K	﹤0.01%	3604
2015 Q4	$593K	Sell	57,410 -6,911	-11%	-$68.7K	﹤0.01%	3240
2015 Q3	$734K	Sell	64,321 -118,988	-65%	-$1.59M	﹤0.01%	3107
2015 Q2	$2.74M	Buy	183,309 +111,854	+157%	+$1.27M	﹤0.01%	2290
2015 Q1	$645K	Buy	71,455 +4,102	+6%	+$42.5K	﹤0.01%	3356
2014 Q4	$819K	Sell	67,353 -819	-1%	-$9.05K	﹤0.01%	3316
2014 Q3	$666K	Buy	68,172 +14,684	+27%	+$180K	﹤0.01%	3404
2014 Q2	$683K	Sell	53,488 -86,270	-62%	-$839K	﹤0.01%	3606
2014 Q1	$1.48M	Buy	139,758 +2,475	+2%	+$26.4K	﹤0.01%	2776
2013 Q4	$1.04M	Buy	137,283 +123,514	+897%	+$782K	﹤0.01%	3242
2013 Q3	$100K	Sell	13,769 -57,956	-81%	-$294K	﹤0.01%	4108
2013 Q2	$111K	Buy	+71,725	New	+$124K	﹤0.01%	3998

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Credit Suisse's BCRX Position: Q1 2024 in Review

Credit Suisse held its BioCryst Pharmaceuticals (BCRX) position steady in Q1 2024 at 229,544 shares worth $1.17M. The position accounts for ﹤0.01% of the portfolio, ranked #2172.

Credit Suisse first reported a position in BCRX in Q2 2013 and has held it in 44 quarters since. The position peaked at $11.3M in Q2 2021. 238 funds tracked by Wall St. Rank hold BCRX as of Q1 2024.

Credit Suisse held 229,544 shares of BioCryst Pharmaceuticals worth $1.17M as of Q1 2024.
Credit Suisse left its BioCryst Pharmaceuticals share count unchanged in Q1 2024.
BioCryst Pharmaceuticals made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2172 holding.
Credit Suisse first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 44 quarters since.
Credit Suisse's BioCryst Pharmaceuticals position peaked at $11.3M in Q2 2021.
238 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.